HomepageSBHMY • OTCMKTS
add
Sino Biopharmaceutical Unsponsored Caymand Islands ADR
Vorige slotkoers
$Â 7,75
Jaar-range
$Â 6,69 - $Â 9,65
Beurswaarde
53,96Â mld. HKD
Gem. volume
58,00
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (CNY) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 7,94Â mld. | 11,14% |
Bedrijfskosten | 4,78Â mld. | 10,58% |
Netto inkomsten | 1,51Â mld. | 139,69% |
Netto winstmarge | 19,01 | 115,78% |
Winst per aandeel | — | — |
EBITDA | 1,98Â mld. | 8,88% |
Effectief belastingtarief | 16,99% | — |
Balans
Totale activa
Totale passiva
| (CNY) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 13,18Â mld. | -15,93% |
Totale activa | 66,70Â mld. | 1,62% |
Totale passiva | 24,58Â mld. | -15,76% |
Totaal aandelenvermogen | 42,12 mld. | — |
Uitstaande aandelen | 18,21 mld. | — |
Koers-boekwaardeverhouding | 4,31 | — |
Rendement op activa | 6,50% | — |
Rendement op kapitaal | 8,37% | — |
Kasstroom
Nettomutatie in liquide middelen
| (CNY) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 1,51Â mld. | 139,69% |
Operationele kasstroom | 1,54Â mld. | 15,25% |
Kasstroom uit beleggingen | -1,02Â mld. | 49,91% |
Kasstroom uit financiering | -2,05Â mld. | -1,42% |
Nettomutatie in liquide middelen | -1,52Â mld. | 43,37% |
Vrije kasstroom | 1,09Â mld. | 36,59% |
Over
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020.
The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
CEO
Opgericht
2000
Website
Werknemers
24.437
